ArticleThe oncologist2019
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of the Economic Status of the Patient's Country of Residence on the Outcome of Oncology Clinical Trials.The oncologist · 2022Pooled it
- Estimated HPV-Attributable Inpatient Pharmaceutical Reimbursement in Bulgaria, 2021-2025: A National Payer-Perspective Expenditure Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Methodological aspects of economic evaluations and health economic models in glioblastoma: A systematic literature review.Neuro-oncology practice · 2026Review
- Long-Term Trends and Projections of Multiple Myeloma Across Three Continents: A Comparative Study of China, the United States of America, the Russian Federation, England and France (1990-2036).Cancer medicine · 2025Article
- Article
- Tearing down inequalities in the healthcare system across Europe: the BEACON project.Frontiers in public health · 2025Review
- Risk Factors and Preventive Measures for Breast Cancer.Journal of clinical medicine · 2024Article
- Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.Journal of clinical medicine · 2024Article
- Patients' perspectives on cancer care disparities in Central and Eastern European countries: experiencing taboos, misinformation and barriers in the healthcare system.Frontiers in oncology · 2024Article
- Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.ESMO open · 2023Article
- Perspectives for Cancer Care and Research in Central and Eastern Europe.Oncology research and treatment · 2023Review
- Procurement of medicines to treat cancer, 2015-2020, China.Bulletin of the World Health Organization · 2022Article
- COVID-19 Pandemic Effects on Breast Cancer Diagnosis in Croatia: A Population- and Registry-Based Study.The oncologist · 2021Article
- Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto.Breast (Edinburgh, Scotland) · 2021Article
- Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries.Scientific reports · 2021Article
- Improving Quality Indicator of Melanoma Management - Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study.Frontiers in oncology · 2021Article
- Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment.The oncologist · 2020Article
- Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.The oncologist · 2020Article
- Association Between Spending and Outcomes for Patients With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a steady decline in cancer mortality in Western Europe (WE), but this trend is not so obvious in Central and Eastern Europe (CEE). One of the largest discrepancies between WE and CEE is the level of investment in cancer care. The objective of our analysis was to examine the correlation between mortality-to-incidence (M/I) ratio and expenditures on oncology drugs in CEE and WE. MATERIALS AND
methodsThis cross-sectional analysis was done on publicly available data. Data on expenditures for oncology drugs were obtained from QuintilesIMS, and data on M/I ratio from Globocan. The main outcome was mortality-to-incidence ratio, and the primary analysis was performed by Spearman's rank correlation.
resultsThere is a large discrepancy in expenditure on oncology drugs per cancer case between WE and CEE, and within CEE. Average expenditure on oncology drugs per capita as well as per new cancer case was 2.5 times higher in WE than in CEE. Availability of oncology drugs was highest in Germany (100%), relatively similar in WE (average of 91%), but in CEE it ranged from 37% to 86%, with an average of 70%. Annual expenditures on all oncology drugs per new cancer case was significantly negatively correlated with the M/I ratio (Spearman's ρ = -0.90,
conclusionThere is a financial threshold for oncology drugs per cancer case needed to increase survival. Based on significantly lower expenditures for oncology drugs in CEE in comparison with WE, more investment for drugs as well as better, more organized, value- oriented consumption is needed. IMPLICATIONS FOR PRACTICE: Cancer is not treated equally successfully in Western Europe (WE) and in Central and Eastern Europe (CEE). This study showed that success in treatment of cancer is associated with the amount of money invested in oncology drugs. CEE countries spend on average 2.5 times less than WE countries for oncology drugs per new cancer case. These findings should be used by health care providers and oncologists struggling for more resources and better, more organized, evidence-based allocation of these resources as well as better oncology outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.